TAK-280

DRUG2 trials

Sponsors

Takeda Development Center Americas Inc., Takeda

Conditions

Unresectable Locally Advanced or Metastatic Cancer

Phase 1

First-in-Human Study of TAK-280 in Participants With Solid Tumors

TerminatedNCT05220098

TakedaUnresectable Locally Advanced or Metastatic Cancer

Start: 2022-04-21End: 2025-07-28Updated: 2026-07-07

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer

CompletedCTIS2023-504012-16-00

Takeda Development Center Americas Inc.Unresectable Locally Advanced or Metastatic Cancer

Start: 2024-04-29End: 2025-07-28Target: 56Updated: 2025-07-18

Related Papers

Abstract 1825: QSP modeling to inform dose and regimen selection for TAK-280: A bi-specific antibody.

Cancer Research2026-04-03

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.

Journal of Clinical Oncology2024-06-016 citations